Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 10/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888478 | 1.00 | MAPT (0.52) | MAPTLMNAMAPK1KCNH2HRH3 | |
| SCHEMBL12659739 | 0.91 | CXCR3 (0.50) | MAPTLMNAMAPK1KCNH2HRH3 | |
| SCHEMBL1895441 | 0.90 | PIK3CD (0.48) | MAPTLMNAMAPK1KCNH2HRH3 | |
| SCHEMBL1895439 | 0.90 | PIK3CD (0.48) | MAPTLMNAMAPK1KCNH2HRH3 | |
| SCHEMBL12659743 | 0.88 | CXCR3 (0.54) | MAPTCXCR3 | |
| SCHEMBL12672493 | 0.87 | MAPT (0.54) | MAPTLMNAMAPK1KCNH2HRH3 | |
| SCHEMBL12659757 | 0.85 | CXCR3 (0.53) | MAPTLMNAMAPK1KCNH2HRH3 | |
| SCHEMBL12659732 | 0.82 | PIK3CD (0.48) | MAPTKCNH2HRH3CXCR3 | |
| SCHEMBL14178906 | 0.82 | CXCR3 (0.47) | MAPTLMNAMAPK1ALDH1A1CXCR3 | |
| SCHEMBL5577400 | 0.80 | MEN1 (0.56) | MAPTLMNAMAPK1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939538-B2 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | AMGEN INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20060069099-A1 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | AMGEN SF, LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069099-A1 | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases | MSR1, TNF, HLA-DRB1 | MAPT 2943/4885LMNA 966/4885MAPK1 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.